James Leal Biography and Net Worth

SVP of Tandem Diabetes Care

Jim Leal has served as our Senior Vice President, Operations since August, 2017. Mr. Leal joined Tandem in October 2010 as Vice President, Operations bringing 25 years of manufacturing and engineering experience. Previously, Mr. Leal was the Vice President of Manufacturing and Field Support for Volcano Corporation and held Director Roles with CardioNet, Inc. and Digirad Corporation. He held Senior Engineering roles with FlipChip Technologies and Hughes Aircraft Company. Jim has won several awards including a Hughes Aircraft Doctoral and Masters Fellowship and was a recognized nominee for Most Promising Hispanic Engineer of the Year Award. Mr. Leal is a published author and patent holder. He is a University of Arizona graduate with a PhD in Materials Science and Engineering.

What is James Leal's net worth?: The estimated net worth of James Leal is at least $99,446.54 as of July 27th, 2021. Mr. Leal owns 5,262 shares of Tandem Diabetes Care stock worth more than $99,447 as of March 12th. This net worth approximation does not reflect any other investments that Mr. Leal may own. Learn More about James Leal's net worth.
How do I contact James Leal?: The corporate mailing address for Mr. Leal and other Tandem Diabetes Care executives is 11075 ROSELLE STREET, San Diego CA, 92121. Tandem Diabetes Care can also be reached via phone at (858) 366-6900 and via email at smorrison@tandemdiabetes.com. Learn More on James Leal's contact information.
Has James Leal been buying or selling shares of Tandem Diabetes Care?: James Leal has not been actively trading shares of Tandem Diabetes Care during the last ninety days. Most recently, James Leal sold 1,906 shares of the business's stock in a transaction on Monday, December 27th. The shares were sold at an average price of $151.45, for a transaction totalling $288,663.70. Learn More on James Leal's trading history.
Who are Tandem Diabetes Care's active insiders?: Tandem Diabetes Care's insider roster includes David Berger (EVP), Kim Blickenstaff (Director), Elizabeth Gasser (EVP), Brian Hansen (EVP), James Leal (SVP), Kathleen McGroddy-Goetz (Director), Susan Morrison (EVP), Rebecca Robertson (Director), John Sheridan (CEO), Christopher Twomey (Director), and Leigh Vosseller (CFO). Learn More on Tandem Diabetes Care's active insiders.
Are insiders buying or selling shares of Tandem Diabetes Care?: In the last twelve months, Tandem Diabetes Care insiders bought shares 2 times. They purchased a total of 11,070 shares worth more than $203,312.24. In the last twelve months, insiders at the medical device company sold shares 3 times. They sold a total of 25,000 shares worth more than $858,400.00. The most recent insider tranaction occured on March, 7th when COO Jean-Claude Kyrillos bought 10,538 shares worth more than $190,948.56. Insiders at Tandem Diabetes Care own 2.2% of the company. Learn More about insider trades at Tandem Diabetes Care.
Information on this page was last updated on 3/7/2025.

James Leal Insider Trading History at Tandem Diabetes Care

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/27/2021	Sell	1,906	$151.45	$288,663.70
11/29/2021	Sell	1,905	$130.96	$249,478.80
10/27/2021	Sell	1,904	$130.34	$248,167.36
9/27/2021	Sell	1,905	$121.72	$231,876.60
9/7/2021	Sell	3,574	$123.00	$439,602.00
8/27/2021	Sell	1,667	$110.64	$184,436.88
7/27/2021	Sell	1,666	$102.25	$170,348.50	5,262
6/28/2021	Sell	7,135	$100.00	$713,500.00	10,263

James Leal Buying and Selling Activity at Tandem Diabetes Care

Tandem Diabetes Care Company Overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Today's Range

Now: $18.90

$18.03

$19.34

50 Day Range

MA: $32.43

$17.89

$37.53

2 Week Range

Now: $18.90

$17.64

$53.69

Volume

696,203 shs

Average Volume

1,470,901 shs

Market Capitalization

$1.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45